Amy Weinfeld Schulman

Add links
From Wikipedia, the free encyclopedia

Amy Weinfeld Schulman is an American healthcare biotech venture capitalist who serves as a managing partner at Polaris Partners and a trained lawyer.[1][2][3] She focused on investing in healthcare companies and early-stage biotech start-ups.[2][4] She also chairs the Board of Directors for Alnylam Pharmaceuticals (NASDAQ: ALNY)[5] and ByHeart,[6][7] and represents Polaris as a director for Kallyope, Thirty Madison, QurAlis, and Larkspur.[8] She also practiced as a lawyer.

Early life[edit]

Both her parents practiced law and were the first in their families to attend college.[9] Her mother, Ann, graduated at the age of 45 and her father after he had served in the US coast guards.[9]

Education[edit]

She is a Phi Beta Kappa graduate of Wesleyan University, where she received a joint degree in philosophy and English, and she obtained her J.D. from Yale Law School.[2][4][10]

Career[edit]

Schulman currently serves as a managing partner at Polaris Partners, which focuses on investing in healthcare companies and early-stage biotech start-ups.[11][12] She also co-founded the Polaris Innovation Fund, which she has managed since its inception in 2017.[13][2] She serves as chair of the Board of Directors of Alnylam Pharmaceuticals (NASDAQ: ALNY) and as chair of the Board of Directors of ByHeart.[14] [15] She also represents Polaris as a director on various boards, including Thirty Madison, QurAlis, and Larkspur.[2][8][16]

Before joining Polaris in 2014, Amy held various roles at Pfizer, beginning with general counsel and moving to the business side as president of Pfizer Nutrition and president of Pfizer Consumer Healthcare.[11] Initially serving as the general counsel, she later transitioned to the business side,[4] becoming the president of both Pfizer Nutrition and Pfizer Consumer Healthcare.[17][18] Prior to her tenure at Pfizer, she practiced law as a partner at DLA Piper and began her career in litigation at Cleary Gottlieb Steen & Hamilton in 1991.[19][20]

Philanthropy[edit]

Amy is active in philanthropic circles and also serves on the Boards of Action Against Hunger, Mount Sinai Hospital (where she co-chairs the Innovations Committee), and the California Institute of Technology.[21] [2] She is a member of Singapore’s Health and Biomedical Sciences International Advisory Council and the LifeSci NYC Advisory Council.[2][1][8]

Recognition[edit]

Amy has received numerous awards, including the Margaret Brent Women Lawyers of Achievement Award, Scientific American’s Worldview 100 List, Fierce Biotech’s Top 15 Women in Biotech, and Fortune Magazine’s 50 Most Powerful Women in Business.[22][23][1]

Personal life[edit]

Schulman is married to David Nachman, and together, they have three children: Ezra, Gideon, and Rafael. Amy and David reside in Brooklyn, New York.[9][24]

References[edit]

  1. ^ a b c "Amy Schulman | Polaris Partners". Retrieved 2024-03-22.
  2. ^ a b c d e f g "Ms. Amy Schulman - Board of Trustees". board.caltech.edu. Retrieved 2024-03-22.
  3. ^ "Amy Schulman Elected as New Caltech Trustee". California Institute of Technology. 2023-09-13. Retrieved 2024-03-22.
  4. ^ a b c "Amy Schulman '89 | Yale Law School". law.yale.edu. Retrieved 2024-03-22.
  5. ^ "Alnylam Elects Amy Schulman to its Board of Directors". fiercepharma.com.
  6. ^ ByHeart. "ByHeart Appoints Amy Schulman as Chair of the Board of Directors, Further Solidifying its Position as a Leader in the Infant Nutrition Category". www.prnewswire.com (Press release). Retrieved 2024-03-22.
  7. ^ "ByHeart adds Amy Schulman and Hemi Zucker to Board along with raising $70m Series A financing led by Polaris Partners, OCV Partners and D1 Capital Partners". talent4boards.com.
  8. ^ a b c "Amy Schulman". www.astp4kt.eu. Retrieved 2024-03-22.
  9. ^ a b c "Amy Schulman Weds a Lawyer". The New York Times. 1987-08-17. ISSN 0362-4331. Retrieved 2024-06-04.
  10. ^ "Trustees Emeriti, Board of Trustees - Wesleyan University". www.wesleyan.edu. Retrieved 2024-03-22.
  11. ^ a b "Ex-Pfizer exec Schulman lands at Polaris after an abrupt departure". fiercebiotech.com.
  12. ^ "About | Polaris Partners". Retrieved 2024-06-04.
  13. ^ "Polaris Innovation Fund | Polaris Partners". Retrieved 2024-06-04.
  14. ^ Fractyl. "Amy Schulman". Fractyl. Retrieved 2024-06-04.
  15. ^ "Amy Schulman - Director at ByHeart". THE ORG. Retrieved 2024-06-04.
  16. ^ Fishburn, C Simone. "Amy Schulman on the draw of Singapore, and more – The BioCentury Show". BioCentury. Retrieved 2024-06-04.
  17. ^ "Amy Schulman". Cardurion. Retrieved 2024-03-22.
  18. ^ "Amy Schulman, tapped to lead a new Pfizer division, makes an abrupt exit". fiercepharma.com.
  19. ^ "Leadership in Law: Amy Schulman at DLA Piper - Case - Faculty & Research - Harvard Business School". www.hbs.edu. Retrieved 2024-03-22.
  20. ^ "Pfizer's Amy Schulman on What Women Need to Succeed in their Careers". Knowledge at Wharton. Retrieved 2024-03-22.
  21. ^ "Board of Directors". Action Against Hunger. Retrieved 2024-06-04.
  22. ^ "Previous Margaret Brent Women Lawyers of Achievement Award Recipients".
  23. ^ "What if we stopped trying to change the people, and we changed the pill instead?". TEDMED. Retrieved 2024-06-04.
  24. ^ "Ms. Schulman to Wed David Nachman". The New York Times. 1987-04-19. ISSN 0362-4331. Retrieved 2024-06-04.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Amy_Weinfeld_Schulman&oldid=1227198158"